Did you mean: Catlett v. Boehringer Ingelheim Pharmaceuticals Inc et al?
Web Results

TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

ANUSHAVAN G. TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. PETERS, C. J. The principal issue in this appeal is whether there was ...

In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation

www.law360.com/cases/502983dbe1a1455469000001

Boehringer Ingelheim International GmbH has agreed to pay roughly $650 million to settle claims in multidistrict ... Richard W Cohen, Lowey Dannenberg et al.

The Role of STAT3 in Non-Small Cell Lung Cancer

www.ncbi.nlm.nih.gov/pmc/articles/PMC4074799/

Mar 26, 2014 ... First, Barre et al. reviewed that the STAT3 oncogenic pathway was associated with .... Chugai Pharmaceutical Company and Boehringer-Ingelheim in Japan. .... Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., ..... Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al.

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo ...

mct.aacrjournals.org/content/early/2012/10/01/1535-7163.MCT-12-0311.full.pdf

Chemical Company, Gumi-City, Kyungbuk, Republic of Korea; 7Depart- ment of Pharmacology ... AstraZeneca, Boehringer Ingelheim Pharma, and Pfizer, respectively. AG490 ... Kim et al. Mol Cancer Ther; 11(10) October 2012. Molecular Cancer Therapeutics. OF2 ... in 0.5% (w/v) methylcellulose containing 0.4% Tween 80.

Cellular responses to murine CD40 in a mouse B cell line may be ...

onlinelibrary.wiley.com/doi/10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y/full

Dec 13, 2001 ... ... the delay in NF-κB activation found in TRAF2-deficient mice by Mak et al. ..... 800 μF and 250 V. Selection of transfectants commenced no sooner than 12 h ... was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). ..... Hostager, B. S., Catlett, I. M. and Bishop, G. A., Recruitment of CD40 and ...

Homeostasis model assessment of insulin resistance does not seem ...

onlinelibrary.wiley.com/doi/10.1002/hep.26437/full

Oct 17, 2013 ... Stanislas Pol: Consultant for Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Vertex ... The REALIZE trial was funded by Janssen Pharmaceuticals and Vertex ... In a study by Romero-Gomez et al.,[11] the effect of IR on SVR was ... Plasma HCV RNA was measured using the COBAS TaqMan assay, v.

PDF(304K) - Wiley Online Library

onlinelibrary.wiley.com/doi/10.1002/hep.24651/pdf

Sciences, Inc., Merck & Co., Three Rivers Pharmaceuticals, LLC, and Vertex Pharmaceuticals, Inc. Continuing Medical ... He received grants from Gilead, Boehringer Ingelheim, Siemens, and Anadys. He holds ... Pineda et al. reported a 5-year incidence ..... V. Noncirrhotic portal hypertension in HIV-infected patients: unique.

The hypercoagulable state in patients - Maastrichtuniversity.nl

digitalarchive.maastrichtuniversity.nl/fedora/get/guid:109afe22-c219-4f43-abe4-bd8124d501b7/ASSET1

Financial support by AstraZeneca, Bayer Schering Pharma, Boehringer Ingelheim, ..... Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al ..... Taylor FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R et al. ..... trypsin inhibitor (CTI; Haematologic Technologies Inc, Essex Junction, VT, USA), a.

Arkansas Secretary of State

www.sos.arkansas.gov/elections/documents/20120103_ar_sos_registered_lobbyists.pdf

Jan 3, 2012 ... Pharmaceutical Research & Manufacturers of America. Client or Employer .... Boehringer Ingelheim Pharmaceuticals, Inc. Client or ..... c/o Nielsen Merksamer, et al. 2350 Kerner ..... Catlett Law Firm, PLC ..... Donald V Allen.

Cases Argued And Determined - Illinois Secretary of State

www.cyberdriveillinois.com/departments/court_of_claims/volume39.pdf

Jul 1, 1986 ... 1987, ch. 37, par. 439.1 et seq. The Court of Claims has exclusive jurisdiction to hear and determine the following matters: (a) all claims against ...

More Info

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

2012 Eighth Circuit U.S. Court of Appeals Case Law, Court Opinions ...

law.justia.com

Kuhn v. Wyeth, Inc. Date: July 26, 2012. Docket Numbers: 11-1809, 11-1815 ...... States v. Phillip Catlett ..... Boehringer Ingelheim Pharmaceuticals, Inc., et al.

Persistent STAT3 Activation in Colon Cancer Is Associated with ...

www.ncbi.nlm.nih.gov

All operations on live animals were performed under isoflurane anesthesia ( CuraMed Pharma, ..... We acknowledge traveling grants by the Boehringer Ingelheim Fund to F.C. and ... Di Quirico D, Donati V, Berti P, Spisni R, Galleri D, Materazzi G, et al. ... Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, ...